Jazz Pharmaceuticals PLC

JAZZ

165.500USD

+2.350+1.44%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Jazz Pharmaceuticals PLC's Score

Industry at a Glance

Industry Ranking

20 / 159

Overall Ranking

63 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Jazz Pharmaceuticals PLC Highlights

StrengthsRisks

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Undervalued

The company’s latest PE is -27.36, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 62.93M shares, decreasing 12.50% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 106.37K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.17.

Analyst Rating

Based on 17 analysts

Buy

Current Rating

216.954

Target Price

+32.98%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Jazz Pharmaceuticals PLC is 8.49, ranking 64 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 1.13B, representing a year-over-year increase of 6.74%, while its net profit experienced a year-over-year increase of 16.91%.

Score

Industry at a Glance

Previous score

8.49

Change

0



Financials

6.49

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.01

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.48

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.50

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Jazz Pharmaceuticals PLC is 8.69, ranking 10 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -27.36, which is -515.01% below the recent high of 113.56 and -268.89% above the recent low of -100.94.

Score

Industry at a Glance

Previous score

8.69

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 20/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Jazz Pharmaceuticals PLC is 8.59, ranking 24 out of 159 in the Pharmaceuticals industry. The average price target is 210.00, with a high of 247.00 and a low of 147.00.

Score

Industry at a Glance

Previous score

8.59

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Jazz Pharmaceuticals PLC is 7.18, ranking 75 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 172.61 and the support level at 158.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.14

Change

0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Jazz Pharmaceuticals PLC is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 103.56%, representing a quarter-over-quarter decrease of 1.73%. The largest institutional shareholder is The Vanguard, holding a total of 5.89M shares, representing 9.70% of shares outstanding, with 0.28% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

5.88M

-3.05%

BlackRock Institutional Trust Company, N.A.

5.01M

-3.99%

Dimensional Fund Advisors, L.P.

2.84M

+11.77%

Capital World Investors

2.55M

+0.41%

LSV Asset Management

2.51M

-1.64%

State Street Investment Management (US)

1.87M

-3.49%

EcoR1 Capital, LLC

1.71M

--

JP Morgan Asset Management

1.70M

+9.83%

Fuller & Thaler Asset Management Inc.

1.63M

-0.17%

Columbia Threadneedle Investments (US)

1.57M

+1.89%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Jazz Pharmaceuticals PLC is 7.07, ranking 44 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.25. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Jazz Pharmaceuticals PLC’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Jazz Pharmaceuticals PLC

JAZZ

8.29 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment